A bbVie has reported encouraging topline outcomes from the first of two replicate trials of the Phase III UP-AA programme, assessing Rinvoq (upadacitinib), at both 15mg and 30mg doses in adult and ...

In July 2025, AbbVie announced top line results from one of two parallel studies of the Phase III UP-AA trial evaluating upadacitinib in alopecia areata (AA).

US pharma major AbbVie recently announced top-line results from one of two parallel studies of the pivotal Phase III UP-AA ...

In moderate to severe Crohn's disease, a network meta-analysis suggested that TNF inhibitor-based therapy was the most ...

Upadacitinib demonstrated significant efficacy in promoting scalp hair regrowth in severe alopecia areata patients, achieving primary endpoints in nearly half of the participants. The phase 3 trials ...

AbbVie (NYSE: ABBV) today announced positive results from a new post-hoc analysis from the Measure Up 1 and Measure Up 2 Phase 3 studies. The analysis evaluated the efficacy of upadacitinib (15 mg ...

In Study 2 of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 44.6% and 54.3% of patients with severe alopecia areata treated ...

Upadacitinib 15 mg demonstrates consistent, sustained efficacy in ankylosing spondylitis through year 1, according to data published in Arthritis & Rheumatology. “Upadacitinib, a JAK inhibitor ...

A phase 3 induction study evaluating upadacitinib for the treatment of adults with moderate to severe ulcerative colitis met its primary and all ranked secondary end points. The multicenter ...

Upadacitinib (UPA) may offer superior pain management for patients with rheumatoid arthritis (RA) compared with adalimumab (ADA). This heightened efficacy may stem from mechanisms that encompass ...

Upadacitinib, a JAK1 inhibitor, is superior to adalimumab and placebo at improving signs, symptoms and physical function among patients with rheumatoid arthritis who have had an inadequate ...

Upadacitinib (Rinvoq) appears effective for atopic dermatitis (AD) in adolescents and adults, with no unexpected safety concerns, according to two new duplicate phase 3 trials. The Measure Up 1 ...